EUVIMEDEUVIMED entdecken
Kohortenstudie

Risk of thyroid cancer associated with glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A population‐based cohort study

Sungho Bea, Heejun Son, Jae Hyun Bae iD, Sun Wook Cho, Ju-Young Shin iD, Young Min Cho iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15292 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Sungho Bea und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, South Korea. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Thyroid Neoplasms. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Ministry of Food and Drug Safety.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To determine the potential association between the use of either glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) or dipeptidyl peptidase‐4 (DPP‐4) inhibitors, and the risk of thyroid cancer in individuals with type 2 diabetes. Materials and Methods This population‐based cohort study used claims data from the Korean National Health Insurance Database, 2014‐2020. Two distinct cohorts were established to compare each incretin‐based drug with sodium‐glucose cotransporter‐2 (SGLT2) inhibitors, chosen as active comparators because of their previous non‐association with thyroid cancer, and their common usage as add‐on therapy to metformin along with GLP‐1RAs and DPP‐4 inhibitors. The first cohort included 21 722 new users of GLP‐1RAs and 326 993 new users of SGLT2 inhibitors, whereas the second cohort included 904 300 DPP‐4 inhibitor new users and 112 017 SGLT2 inhibitor new users. The outcome was the time to incident thyroid cancer. Weighted Cox proportional models were used to estimate hazard ratios of thyroid cancer incidence associated with incretin‐based drugs of interest.

Results

The use of GLP‐1RAs was not associated with an increased risk of thyroid cancer (weighted hazard ratio 0.98, 95% confidence interval 0.62‐1.53) compared with that of SGLT2 inhibitors. Using DPP‐4 inhibitors was also not associated with an increased risk of thyroid cancer (0.95, 0.79‐1.14) compared with that of SGLT2 inhibitors. No significant effect modifications were observed across subgroup analyses. Sensitivity analyses, including alternative outcome definition analysis of medullary thyroid cancer, were consistent with the primary analysis results.

Conclusions

GLP‐1RAs and DPP‐4 inhibitors were not associated with an increased risk of thyroid cancer in individuals with type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dipeptidyl-Peptidase IV InhibitorsDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsThyroid NeoplasmsHumansGlucagon-Like Peptide-1 Receptor AgonistsIncretinsCohort StudiesHypoglycemic AgentsDipeptidyl-Peptidases and Tripeptidyl-Peptidases

Stichwörter der Autor:innen

DPP-4 inhibitorsGLP-1 receptor agoniststhyroid cancertype 2 diabetes

Substanzen

Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsSodium-Glucose Transporter 2 InhibitorsIncretinsHypoglycemic AgentsDipeptidyl-Peptidases and Tripeptidyl-Peptidases

Autor:innen und Institutionen

  • School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
  • Division of Endocrinology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
  • Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
  • Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea.
  • Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, South Korea.

ORCID-Profile: Jae Hyun Bae, Ju-Young Shin, Young Min Cho

Förderung

  • Ministry of Food and Drug Safety

Zitieren

APA

Bea, S., Son, H., Bae, J. H., Cho, S. W., Shin, J. Y., & Cho, Y. M. (2024). Risk of thyroid cancer associated with glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A population‐based cohort study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15292

Vancouver

Bea S, Son H, Bae JH, Cho SW, Shin JY, Cho YM. Risk of thyroid cancer associated with glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A population‐based cohort study. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15292

BibTeX
@article{Bea2024,
  author = {Bea, Sungho and Son, Heejun and Bae, Jae Hyun and Cho, Sun Wook and Shin, Ju-Young and Cho, Young Min},
  title = {Risk of thyroid cancer associated with glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A population‐based cohort study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15292}
}
Kostenlos starten →